Uterine teratoma and the role of short-tandem repeat genotyping in understanding origins.
Uterine teratoma and the role of short-tandem repeat genotyping in understanding origins. Gynecol Oncol Rep. 2024 Dec; 56:101652.
PMID: 39698441
Conventional laparoscopic resection of platinum-sensitive recurrent oligometastatic ovarian cancer lesion in the interaortocaval region.
Conventional laparoscopic resection of platinum-sensitive recurrent oligometastatic ovarian cancer lesion in the interaortocaval region. Int J Gynecol Cancer. 2024 Oct 07; 34(10):1651-1652.
PMID: 38719278
Laparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail.
Laparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail. Int J Gynecol Cancer. 2024 Sep 02; 34(9):1474-1475.
PMID: 38724238
Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients.
Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients. PLoS One. 2024; 19(7):e0305273.
PMID: 38976671
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clin Exp Metastasis. 2024 Oct; 41(5):765-775.
PMID: 38909139
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses.
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Rep. 2024 Jun 20; 2(1):43.
PMID: 39516558
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clin Cancer Res. 2024 May 01; 30(9):1768-1777.
PMID: 38592381
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proc Natl Acad Sci U S A. 2024 Apr 23; 121(17):e2321898121.
PMID: 38625939
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. Br J Cancer. 2024 Apr; 130(6):1073.
PMID: 38438590
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Mol Cancer Ther. 2023 12 01; 22(12):1404-1412.
PMID: 37676984